Cryonics Society Newsfeed

At the high level, without delving into specific mechanisms, the consensus view on aging is that it exists in the shadow of natural selection. The selection pressure that drives the spread of changes in genes, systems, biology in general in any given species operates most strongly on early life reproductive success. This inevitably gives rise to systems that perform well initially, but which fall apart later. Expenditure of resources on long-term maintenance loses out to expenditure of resources on short-term reproductive fitness. Aging is a near universal side-effect of evolutionary competition, a race to the bottom that exists because early life reproductive success wins out over repeated reproductive success for a longer period of time. That a given aspect of an individual's biochemistry can be

Elderly mice on the popular weight-loss drug semaglutide aged slower and lived longer, mimicking the longevity effects of caloric restriction. The post Could GLP-1 Drugs Help You Live a Longer, Healthier Life? appeared first on SingularityHub.

South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward the clinic. Biotech real estate has its own hierarchy, and San Diego sits near the top. So when a Seongnam-based RNA therapeutics company buys itself a desk inside Eli Lilly’s newest innovation outpost there, it’s worth asking The post Rznomics brings RNA editing into Lilly’s San Diego biotech hub appeared first on Longevity.Technology.

Six proteomic clocks detect a younger biological age signal in an IPF trial – but separating geroprotection from treatment remains key. Six proteomic clocks, six different research pedigrees, one direction of travel: that is the headline finding of a new study in Nature Biotechnology, and it is arresting enough on its own terms. The drug The post Rentosertib puts aging clocks to the clinical test appeared first on Longevity.Technology.

PRGS&Tech is South Korea’s only team left in XPRIZE Healthspan’s $110 million race to prove a drug can help everyone age more slowly. Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what The post Lone Korean biotech nears $81m antiaging prize appeared first on Longevity.Technology.

NRG Therapeutics unpacks the molecular switch behind its ALS drug candidate, adding fresh mechanistic evidence to a trial already underway. Longevity.Technology has been following NRG5051 since the earliest days of its preclinical story, through a Parkinson’s UK partnership, a $68.1 million (£50 million) Series B and, this January, the dosing of its first clinical trial The post New ALS drug data reveal a mitochondrial fix appeared first on Longevity.Technology.

The preventive-care clinic adds hormone testing, menopause care and longitudinal risk tracking built specifically around female biology. Ask most women what their annual physical covers, and you’ll get some version of the same answer: not much, and definitely not menopause. It’s a gap Biograph – the preventive health and diagnostics clinic co-founded by Peter Attia The post Biograph builds dedicated women’s preventive health arm appeared first on Longevity.Technology.

In a new study, semaglutide given late in life increased median lifespan in female mice by more than 12% and improved various health markers. Semaglutide’s effect possibly went beyond caloric restriction [1]. Old

Rznomics Inc., a clinical-stage biopharmaceutical based in Seongnam, South Korea, announced that research published online on 4 September in Nucleic Acids Research describes optimized methods for in vitro production of circular RNA. The peer-reviewed paper details systematic target-site selection and P1 construct engineering within an end-to-end self-targeting and splicing workflow and reports up to two-fold The post Rznomics publishes new method to improve circular RNA manufacturing for vaccines, gene therapies appeared first on Longevity.Technology.

Genflow Biosciences PLC reports that its SLAB (Sarcopenia and Longevity in Aged Beagles) randomized, blinded trial of its SIRT6 centenarian gene therapy met the primary endpoint of reduced biological age measured by the GRIM methylation clock. The study enrolled 24 beagle dogs older than 10 years, allocated to four groups: two naked DNA treatment cohorts The post Genflow Biosciences trial meets primary endpoint in aged dogs appeared first on Longevity.Technology.

Insilico Medicine published a study in Nature Biotechnology reporting that its AI-designed idiopathic pulmonary fibrosis candidate rentosertib produced reductions in predicted biological age. The analysis used 12-week longitudinal Olink proteomic data from 42 patients enrolled in a Phase IIa trial and applied six independently developed proteomic aging clocks, all of which indicated biological age reversal The post Insilico AI candidate rentosertib reverses proteomic aging clocks appeared first on Longevity.Technology.

One of the goals of the Dog Aging Project is to better establish that the characteristics of aging in dogs are close enough to the characteristics of aging in humans to make the results of interventions on dog life span relevant to the development of human medicine. Thus the paper here, in which researchers establish that comorbidity, the presence of multiple age-related conditions in the same individual, has much the same relationship with aging and mortality in dogs as it does in people. To have an age-related disease is to have a significant degree of dysfunction in some organ or tissue. The greater the burden of underlying cell and tissue damage resulting from aging, the more likely it is that multiple age-related conditions will emerge.

In recent years, researchers have been gathering as much data as possible on the behavior of aging clocks of various sorts. The study here is an example of the type, in which multiple proteomic clocks were assessed in large epidemiological study populations. As one might expect, where there is age acceleration, meaning a higher clock age than chronological age, this correlates with a greater risk of age-related disease and mortality. Though as noted, clocks don't improve all that much on lifestyle indicators when it comes to the quality of the correlation. This sort of study helps to build a foundation of data as a reference for further exploration of clock behavior in response to interventions thought to affect the pace or state of degenerative aging.

Researchers publishing in Aging Cell have described how stopping growth hormone receptor production in midlife significantly lengthens the lives of mice. Growth but

There are a good many affordable interventions that may well produce enough of an effect on aging to justify widespread use. At the more compelling end of the spectrum, based on a relatively large effect size in animal data and very limited supporting human data, we might consider the senolytic combination of dasatinib and quercetin, stem cell and exosome therapies, and fecal microbiota transplantation from a young donor to an old recipient. Somewhere in the middle lies rapamycin and some bisphosphonate therapies for osteoporosis. At the less compelling end of the list, based on an expectation of smaller positive outcomes and very mixed data for any effect on aging, we find widely used interventions such as hyperbaric oxygen therapy. But we don't know with reasonable

Licensing deal brings Amprion’s misfolded-protein test closer to European trial sites, aiming to speed up neurodegenerative drug development. Long before a patient ever shows a tremor, Parkinson’s disease may already be rewriting the biology of their brain. That gap, between when the disease actually starts and when doctors can currently detect it, is one of The post Amprion expands Parkinson’s test to Europe appeared first on Longevity.Technology.

Deal with Singapore’s MuseCell Innovations could bring $300 million in business and 200 jobs to Celularity’s cell platform. Deals in cell therapy tend to get announced in two flavors: the kind built around a single drug, and the kind built around infrastructure. This unglamorous plumbing decides whether any of these therapies can actually be made The post Celularity lands $300m MuseCell manufacturing deal appeared first on Longevity.Technology.

A newly allowed US patent covers the lipid delivery system behind Daewoong’s experimental mRNA platform for reprogramming aged cells. Patents rarely make for thrilling headlines. They’re procedural, often years behind the science they protect, and written in language designed to be as dry as legally possible. But every so often, a patent allowance is worth The post Daewoong wins US patent nod for antiaging mRNA appeared first on Longevity.Technology.

Fresh off the world’s largest mammalian longevity screen, Longevica names ex-Genentech exec Prasun Mishra to steer science toward the clinic. Longevica Therapeutics has spent the past four years and $13 million running mice through their entire lives to find drugs that might extend ours. Now, with that screening program wrapped, the company has hired someone The post Longevica hires drug-approval veteran as CEO appeared first on Longevity.Technology.

A new 10–15 minute series aims to bring clarity and nuance to the big and bold ideas shaping the future of human longevity. Longevity.Technology has launched Longevity Bites, a new segment running alongside its flagship podcast, Longevity.Technology UNLOCKED. The format is simple on paper: ten to fifteen minutes, one topic, explained properly. In practice, it’s The post Longevity.Technology wants to make longevity make sense appeared first on Longevity.Technology.

iBio will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, 8-10 September 2026. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, will take part in a fireside chat on Tuesday, 8 September at 4:30 p.m. ET. Felipe Duran, Chief Financial Officer, will be available with Dr. Brenner for one-on-one The post iBio to showcase AI-driven antibody pipeline at Wells Fargo Healthcare Conference appeared first on Longevity.Technology.

Longeveron will present at the H.C. Wainwright 28th Annual Global Investment Conference, running from 14 to 16 September 2026 in New York City, with the company’s presentation scheduled for Monday, 14 September, from 1:00 to 1:30 p.m. Eastern Time, and a webcast available via the company’s events and presentations page. Longeveron is a clinical-stage biotechnology The post Longeveron to present cell therapy progress at HC Wainwright conference appeared first on Longevity.Technology.

eGenesis provided a clinical update from an ongoing Expanded Access study of EGEN-2784, its genetically engineered porcine kidney for treatment of kidney failure. The company reports that five patients have received EGEN-2784 transplants since March 2024 in collaboration with the Mass General Brigham health system. According to the company, three patients have achieved sustained kidney The post eGenesis reports clinical update in expanded access kidney study appeared first on Longevity.Technology.

Alkeus announced the publication in JAMA Ophthalmology of TEASE-1 efficacy and safety results for oral Gildeuretinol in Stargardt disease. The randomized, double-masked, placebo-controlled TEASE-1 trial enrolled 50 patients aged 18 to 60 with retinal atrophy at baseline and reported that daily oral Gildeuretinol met the study’s primary endpoint, producing a 21.6% reduction in the transformed The post Alkeus trial shows oral pill slows vision loss in Stargardt disease appeared first on Longevity.Technology.

Mabwell presented Phase Ib/IIa results for its anti-ST2 monoclonal antibody 9MW1911 in patients with moderate-to-severe COPD at ERS 2026. The randomized, double-blind, placebo-controlled, multiple-dose dose-escalation trial enrolled 80 former smokers who received intravenous infusions every four weeks at 100 mg, 300 mg, 600 mg or 900 mg. Pharmacokinetic data showed trough concentrations reached steady state The post Mabwell reports positive Phase 2 trial results for new COPD treatment drug appeared first on Longevity.Technology.

Exosomes are one category of extracellular vesicle secreted by cells, a membrane-wrapped package of molecules, one complex component of the extensive, incompletely mapped communication that takes place constantly between cells. Exosome therapies are conceptually similar to stem cell therapies, an attempt to favorably adjust the behavior of native cells via signaling. While the first exosome therapies are widely available via medical tourism, with a few organizations in the early stages of sponsoring clinical trials to allow use in more regulated regions, the research community is assessing approaches that involve engineering the contents or surface features of exosomes harvested from young donor blood, tissues, or stem cells. The example here is tested in a mouse model of Alzheimer's disease, producing favorable results. In this study, the

Some aspects of cognitive function exhibit marked declines relatively early in later life, by middle age. Here, researchers show that episodic and associative memory recall, meaning the ability to correctly link together and place in context specific individual memories, shows a sizable decline in 50-something participants versus their 20-something counterparts. The fine details of the storage of memories are understood to be fairly dynamic over time; accessing memory can change storage, as can mechanisms of aging operating on the organization of neural networks. Even outside the context of aging, memory is far from perfect even in the best of circumstances. We forget most of our personal histories quite quickly, retaining perhaps 2% of the past according to early research into memory and forgetting. There is

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/. To unsubscribe, send email or reply to this email at newsletter@fightaging.org with "unsubscribe" in the subject or body. Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out more: https://www.fightaging.org/services/ Contents What Can Be Learned About Aging Clocks from Existing Clinical Trial Data for Longevity Interventions? Immune System Signatures Correlate with the Near Term

Computing Why Everyone in Quantum Computing Is Buzzing About Google’s Move Into ‘Neutral Atoms’Adam Bluestein | Fast Company “Google’s interest sends a clear signal: Neutral atom quantum computing has arrived.... The post This Week’s Awesome Tech Stories From Around the Web (Through September 5) appeared first on SingularityHub.

A new system allows agents to orchestrate complex experimental processes and extends Anthropic's reach into the physical world. The post Anthropic’s Claude Can Now Autonomously Run Science Experiments With Lab Equipment appeared first on SingularityHub.

Many of the more sophisticated forms of medicine, including gene therapies and immunotherapies, are challenging to deliver to the brain. At the very least there are far fewer practical options for delivery, and it is possible that none of that that exist fit a given desired use case. The blood-brain barrier stands in the way of intravenous injection as a path for most approaches, blocking passage of most cells and molecules from circulation to brain tissue. While direct injection into the brain or into reservoirs of cerebrospinal fluid can be achieved, they are sufficiently invasive and challenging to rule out commonplace use. The brain is made up of many different cell types, and more sophisticated approaches will want specificity to regions or cell types. Small

eGenesis’ engineered pig kidney kept patients off dialysis for months, including record nine-month stretch before successful human transplant. More than 800,000 Americans live with end-stage kidney disease, and the gap between who needs a transplant and who can get one has only widened. Just 28,000 kidney transplants were performed in the U.S. in 2024, a The post Pig kidneys just bought humans extra years in eGenesis study appeared first on Longevity.Technology.

VHH brings its ‘village’ model to Malaysia, betting that longevity gains only pay off economically if care reaches everyone. Ask most people what caring for an aging population looks like, and they’ll picture a nursing home: a building you move into when you can no longer live independently, cut off from the life you had The post UK elder-care model targets Asia’s aging boom appeared first on Longevity.Technology.

Function Health now lets members feed lab results into ChatGPT, Claude and Perplexity, turning AI answers into ones grounded in biology. Millions of people already type their symptoms into an AI chatbot before they type them into a search bar for a doctor’s office. It’s fast, free and available at 2 a.m. when the worry The post Function connects your lab results to the AI health chatbot you use appeared first on Longevity.Technology.

HCW Biologics received a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to the use of HCW9302 to treat alopecia areata. Together with four recently issued U.S. patents (Nos. 11,401,326; 11,987,619; 12,018,071; 12,516,112) covering compositions, nucleic acids encoding HCW9302, vectors and methods for treating autoimmune diseases, the company says its The post HCW Biologics wins key US patent protection for hair loss drug appeared first on Longevity.Technology.

Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress. The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis Society showing up to 90% PCSK9 silencing and LDL-C reductions up to 68%, with a 0.75 The post Scribe Therapeutics starts first human trial for cholesterol-lowering gene therapy appeared first on Longevity.Technology.

Rapalogix Health has established a dedicated research laboratory at Princeton Innovation Center BioLabs in Princeton, New Jersey. According to the company, the facility expands the company’s internal research capabilities and will serve as the primary site for its translational research program into next-generation rapalogs, the proprietary compound class behind Re-Q Health, the company’s professional skincare The post Rapalogix Health opens Princeton laboratory to advance skin longevity research appeared first on Longevity.Technology.

China’s National Medical Products Administration approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment due to alzheimer’s disease and mild alzheimer’s disease dementia. The approved regimen is 500 mg once weekly, administered as two consecutive 250 mg injections, and patients may switch between intravenous and subcutaneous administration during The post China approves Leqembi subcutaneous autoinjector for early Alzheimer’s appeared first on Longevity.Technology.

FibroBiologics, a Houston-based clinical-stage biotechnology company, announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,721,866 on 1 September 2026, covering therapeutic use of fibroblasts in wound healing. The issued claims, the company says, include methods for topically administering compositions comprising 3D spheroid fibroblasts and fibroblast-derived materials such as extracellular vesicles, The post FibroBiologics granted US patent for fibroblast wound therapy appeared first on Longevity.Technology.

Mito Health has expanded its direct-to-consumer diagnostics marketplace into seven categories of preventive testing and, according to the company, has run more than one million lab tests. The company claims its catalog now includes more than 1,000 individual lab tests and panels, at-home test kits shipped nationwide, at-home blood draws in 35 states, imaging and The post Mito Health passes one million tests, expands preventive offerings appeared first on Longevity.Technology.

Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence, will be included in the HKEX Tech 100 Index following methodology enhancements announced on 18 August 2026 that broaden exposure to emerging technology themes across the AI value chain. The changes will be implemented after the market close on 11 September 2026 and The post Insilico Medicine included in HKEX Tech 100 Index appeared first on Longevity.Technology.

Researchers here suggest that increased ERBB4 expression in neurons is an important driving mechanism in the onset and progression of Alzheimer's disease. One has to be cautious with such findings, even given the effort made by the researchers to show that human data is compatible with the hypothesis, because the mouse models of Alzheimer's disease in which these sorts of discovery are made are very artificial. Mice do not normal exhibit anything like Alzheimer's disease, so the models induce forms of dysfunction that result in something resembling Alzheimer's in humans. The model embodies assumptions about relevant mechanisms that may not be correct, and this is one of the reasons why progress towards therapies has been slow and painful. Single-nucleus RNA-sequencing analysis identified the emergence of

This is far from the only study to indicate that the children of long-lived individuals tend also to be long-lived. The open question is the degree to which this is genetic versus cultural transmission. The construction of very large population databases over the past few decades has produced evidence for genetics to play only a small role in life expectancy for the vast majority of people. Similarly the weight of evidence for lifestyle choice, particularly physical fitness, to be the presently dominant influence on life expectancy is compelling. Against that background, the hypothesis that centenarians are centenarians because they have favorable gene variants that might form the basis for age-slowing therapies faces an uphill battle. Centenarian lifespan extension is frequently accompanied by delayed onset of

Filmmaker Tim Maupin has spent a number of years developing The Last Generation to Die, a near-future film about what happens when the first

Biotech posts $819.9m war chest and full slate of late-stage trial data as it races to become first FDA-approved oral drug for hair loss. Hair loss has always been treated like a cosmetic footnote in medicine, something to manage quietly rather than a condition worth serious drug development. Dermatologist-founded, late clinical-stage biopharmaceutical company Veradermics is The post Veradermics builds $820m war chest for oral hair loss pill appeared first on Longevity.Technology.

850 patients signed up for an Alzheimer’s trial needing 760. For a biotech betting everything on one pill, that’s the good kind of surprise. Trial enrollment is the part of drug development nobody writes headlines about. It’s slow, unglamorous and it’s also where a lot of promising drugs quietly die, not because the science failed, The post Annovis sails past enrollment goal on Alzheimer’s appeared first on Longevity.Technology.

LifespanningRx has launched the Peptide Explorer, an online educational tool designed to help users organize health goals and explore up to three peptide therapy candidates before clinical evaluation. The company says the experience takes about five minutes and uses a structured questionnaire covering areas such as energy and metabolism, body composition, recovery, healthy aging, cognitive The post LifespanningRx launches peptide explorer for clinician-guided reviews appeared first on Longevity.Technology.

Minicircle was named one of 10 finalists in the seven-year, $101 million XPRIZE Healthspan competition, placing the Austin, Texas gene therapy developer among contenders seeking measurable rejuvenation in adults aged 50 to 80. The competition drew about 1,400 teams from 58 countries; 600 entries were reviewed, and 40 teams previously received $250,000 to support early The post Minicircle named XPRIZE Healthspan finalist appeared first on Longevity.Technology.

According to United Therapeutics, the U.S. Food and Drug Administration has accepted a supplemental new drug application for nebulized Tyvaso (treprostinil) inhalation solution to treat idiopathic pulmonary fibrosis, and the company anticipates the agency’s review to be complete in late April 2027. The company claims that, if approved, nebulized Tyvaso would be the first and The post United Therapeutics seeks FDA approval for inhaled treatment for idiopathic pulmonary fibrosis appeared first on Longevity.Technology.

Driven by ongoing support from their community, The Longevity Science Foundation is extending the deadline for the Invested in Her campaign to October 1, 2026, as they work toward a $250,000 fundraising target to support early-stage

USPTO grant strengthens Alterity’s IP position and opens a path for ATH434 into Parkinson’s disease investment. Patents rarely make headlines outside the biotech trade press, but for a clinical-stage company preparing to enter a pivotal trial, a strong patent estate can matter as much as the data itself. Alterity Therapeutics has just secured one of The post New patent strengthens Alterity’s Parkinson’s investment appeared first on Longevity.Technology.

THPharm already has a drug in late-stage trials. Now it’s using AI to work backwards and find out what else that drug might be good for. Drug development usually runs in one direction: pick a disease, search for a molecule that treats it, spend years finding out if you’re right. THPharm, a South Korean biotech The post AI hunts new uses for Phase 3 metabolic drug appeared first on Longevity.Technology.

Exonate Limited has changed its name to Foventa Therapeutics and shifted its focus to clinical development for non-proliferative diabetic retinopathy. The new name is inspired by the fovea, and the company describes its motto as Simply Sharper. According to the company, Foventa is advancing FOV407, a topical retinal-penetrant small molecule SRPK1 inhibitor designed to act The post Exonate rebrands as Foventa Therapeutics to advance diabetic eye drop therapy appeared first on Longevity.Technology.

NorthStrive Biosciences has executed a First Amendment to its Development and License Agreement with Yuva Biosciences to launch a three-phase Expansion Program that will advance four AI-discovered small-molecule compounds toward lead nomination for potential cardiac disease and obesity therapeutics. The Expansion Program is structured to take approximately six months and builds on positive Phase III The post NorthStrive expands AI program with Yuva to nominate cardiac leads appeared first on Longevity.Technology.

Resolution Therapeutics has partnered with Blood Centers of America to support broad U.S. patient access to RTX001, its experimental Regenerative Macrophage Therapy for end-stage liver disease. The partnership will make BCA a preferred provider of cell collection and processing services for pivotal U.S. study sites and aims to enable treatment in community settings where most The post Resolution Therapeutics, BCA partner to expand access to experimental liver disease therapy appeared first on Longevity.Technology.

Oligomerix appointed Cara Cassino, M.D., as interim president and chief executive officer on 31 August 2026. According to the company, Cassino has 25 years of clinical drug development and commercialization experience across large pharmaceutical and biotech firms and more than 25 FDA and EMA drug approvals. Cassino has held senior roles at Boehringer Ingelheim and The post Oligomerix appoints new interim CEO to advance Alzheimer’s drug pipeline appeared first on Longevity.Technology.

As AI eats traffic, the best sites are locking it out, making reliable information harder to find. The post Content for Clicks: AI Is Tearing Up the Web’s Social Contract appeared first on SingularityHub.

Properly untangling aging means untangling its various counterbalances, sometimes on the individual level. Here’s what’s been investigated this month. Interviews Wei-Wu He: People Should Become the

Nature Medicine publication and late-breaking data put ImmunoBrain’s checkpoint immunotherapy and its clean safety profile in the spotlight. While much of Alzheimer’s drug development chases the disease’s hallmark proteins directly, ImmunoBrain Checkpoint is making its case from a different angle entirely: strengthening the body’s own immune system so it can help protect and repair the The post ImmunoBrain’s immune reset shows promise in Alzheimer’s appeared first on Longevity.Technology.

Longevity is becoming big business, but the science, standards and clinical practices needed to guide the field are still catching up. Longevity medicine is having a moment. Biological age tests, epigenetic clocks, peptide protocols, microbiome panels and increasingly elaborate health packages are no longer confined to the fringes of medicine. They are showing up in The post Who decides what counts as longevity medicine? appeared first on Longevity.Technology.

One-year trial results show most patients kept off GLP-1-induced weight loss after a single endoscopic procedure. GLP-1 drugs have transformed obesity treatment, but they have also created a new clinical problem: what happens when patients stop taking them. Weight regain after discontinuation is common and well documented, and it has opened a commercial opportunity for The post Fractyl Health’s Revita data show lasting weight loss appeared first on Longevity.Technology.

Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The recommendation could lead to provincial and territorial funding decisions that expand access in Canada. According The post Canada recommends public funding for Alzheimer’s drug Leqembi appeared first on Longevity.Technology.

Oligomerix has appointed Dr. Cara Cassino as interim president and chief executive officer as the privately held biotech moves from discovery toward clinical development of its lead Alzheimer’s candidate. Cassino has served on the Oligomerix board since July 2025 and brings about 25 years of clinical drug development and commercialization experience that includes senior roles The post Oligomerix appoints new interim CEO to lead Alzheimer’s drug development appeared first on Longevity.Technology.

NeuroSense has redesigned its PrimeC development plan in amyotrophic lateral sclerosis to pursue a potential regulatory submission faster and at materially lower cost than its previously planned path. The program is structured as three focused elements: AI-enabled modeling of Phase 2b PARADIGM clinical data to characterize PrimeC’s formulation contribution, an active-comparator clinical study directly against The post NeuroSense speeds PrimeC path to potential approval in ALS appeared first on Longevity.Technology.

Celularity and MuseCell Innovations have agreed to establish U.S. manufacturing of Dezawa MuseCells at Celularity’s Florham Park, New Jersey, facility, with initial production to include DMCs and DMC-derived products such as Dezawa MuseExosomes and Dezawa MuseSecretome. The initial effort will focus on MCI-authenticated DMC preparations from qualified perinatal, bone marrow and adipose starting materials manufactured The post Celularity, MuseCell Innovations to build US Dezawa MuseCell plant appeared first on Longevity.Technology.

Delivered by injection, the drug transforms astrocytes into neurons. In an early study, mice modeling Alzheimer's showed marked improvement compared to untreated peers. The post This Drug Makes New Neurons in the Brain. Scientists Say It Reversed Alzheimer’s Symptoms in Mice. appeared first on SingularityHub.

Researchers have found that the sirtuin SIRT1 stabilizes the human genome by suppressing retrotransposition, which occurs when parts of the genome transcribe themselves onto other parts. When DNA modifies itself Long

NeuroQuant clearance automates amyloid quantification for Alzheimer’s imaging, trading radiologist’s judgment call for standardized number. Reading a brain scan for Alzheimer’s has long come down to a radiologist’s trained eye and best guess. That guesswork just got a software co-pilot with the FDA’s sign-off attached. Cortechs.ai announced on 18 August that its NeuroQuant PET platform The post FDA clears software that quantifies amyloid in Alzheimer’s appeared first on Longevity.Technology.

United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona. Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population The post United Therapeutics presents positive Phase 3 lung disease study data appeared first on Longevity.Technology.

LifeVantage reported declines in revenue and earnings for the fourth quarter and full fiscal year 2026. For the quarter ended 30 June 2026, revenue was $42.4 million, down 23.1% year over year; net income per diluted share was $0.10 and adjusted earnings per diluted share were $0.11. Adjusted EBITDA for the quarter was $2.7 million. The post Lower order volume, GLP-1 system slump drive down LifeVantage fiscal 2026 sales appeared first on Longevity.Technology.

Mission Therapeutics and NeuraLight have partnered to deploy NeuraLight’s eye-movement-derived brain function biomarkers across Mission’s multinational MTX325 trial in Parkinson’s disease, spanning clinical sites in the UK, Europe and Australia. NeuraLight’s platform will provide objective, repeatable measures intended to quantify neural pathway function and detect subtle changes that conventional clinical scales may miss. MTX325 is The post Mission Therapeutics, NeuraLight partner on Parkinson’s biomarkers appeared first on Longevity.Technology.

Fresh NIH funding backs an iPSC-and-AI push to find drugs for Duchenne cardiomyopathy without relying on mouse models that rarely translate. By the numbers, the translational gap is expensive. Roughly nine in ten drug candidates that succeed in animal models still fail once they reach human trials, and cardiology has one of the worst records The post Greenstone bets on human cells to fix DMD hearts appeared first on Longevity.Technology.

Afterlife: freeze and upload  Eurozine

Every week, we scour the web for important, insightful, and fascinating stories in science and technology. The post This Week’s Awesome Tech Stories From Around the Web (Through August 29) appeared first on SingularityHub.

Recursive self-improvement, where AI continuously builds better versions of itself, might be harder than some hope. The post Are We on the Verge of an Intelligence Explosion? Maybe Not. appeared first on SingularityHub.

Michael Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University, is obsessed with health-tracking wearables. During our interview, he wore four wrist-worn devices – watches

AstronauTx has exercised its Saniona option, advancing a sleep-focused neurodegeneration candidate toward IND-enabling studies. Sleep has become one of the most talked-about levers in longevity science, credited with everything from metabolic health to cognitive resilience. AstronauTx, a UK biotech founded by SV Health’s Dementia Discovery Fund, is now translating that interest into a drug pipeline. The post AstronauTx turns sleep into new dementia target appeared first on Longevity.Technology.

Health-testing company pairs its member data with NYU Grossman’s clinical expertise to try to catch diseases before symptoms ever show up. Most of medicine still works the same way it did a century ago: something goes wrong, a person notices and only then does the system spring into action. Function Health thinks that order of The post Function, NYU take aim at disease before diagnosis appeared first on Longevity.Technology.

BTT Medical Institute, in collaboration with BTT Corp., has initiated a first-in-human clinical and biological safety trial (ClinicalTrials.gov Identifier: NCT07564440) to evaluate induced hyperthermia delivered by the Abreu BTT 700 Temperature Management System, a noninvasive computerized, brain-guided platform that raises body temperature into a controlled fever range through cyclical thermal modulation. The trial, approved by The post BTT begins first human safety trial using heat therapy for ALS appeared first on Longevity.Technology.

Celularity and MuseCell Innovations announced a U.S. manufacturing collaboration to establish production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility. The initial program is intended to authenticate and manufacture Dezawa MuseCells from qualified perinatal, bone marrow or adipose sources using the licensed Dezawa Method and to include manufacturing of DMC-derived products such as The post Celularity to manufacture Dezawa MuseCells in US appeared first on Longevity.Technology.

AlzeCure will present at the Pareto Securities 17th Annual Healthcare Conference in Stockholm on 2 September, with CEO Martin Jönsson scheduled to deliver a presentation and answer questions. The presentation and one-on-one meetings are planned at Hotel At Six, Brunkebergstorg 6, with the company scheduling the session for 17:05-17:25 CEST and saying the presentation will The post AlzeCure to showcase Alzheimer’s, pain research at Pareto Healthcare Conference appeared first on Longevity.Technology.

Can AI replace lawyers—at least in some circumstances? The post An ‘AI Legal Team’ Has Won Its First Case. It’s a Rare Victory for Access to Justice. appeared first on SingularityHub.

A recent study has examined whether senescence might allow cancer cells to survive oncogene withdrawal and become even more dangerous [1]. Some blocking techniques are temporary Many

Seven months after ditching paper screening for Creyos, Claremedica is catching over 90% of new dementia cases at the earliest stage. Cognitive decline is often the one vital sign primary care does not routinely check. Claremedica, a value-based senior primary care organisation serving more than 34,000 Medicare Advantage patients across 35-plus sites in Florida, is The post Claremedica’s digital test finds 90% of new dementia cases early appeared first on Longevity.Technology.

Oligonucleotide drug slows Alzheimer’s decline across every dose tested in Phase 2 and reframes the field’s central therapeutic target. The Alzheimer’s Association International Conference has spent the last several years dominated by amyloid. This year, tau got its moment. Ionis Pharmaceuticals and partner Biogen presented full Phase 2 CELIA data for diranersen, an antisense oligonucleotide The post Ionis, Biogen deliver new tau data in Alzheimer’s appeared first on Longevity.Technology.

Oura Health is preparing for a potential U.S. initial public offering that could raise up to $3 billion and value the smart ring maker at more than $16 billion. The company filed confidentially for the IPO in May and has retained Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co. and Jefferies as underwriters. The The post Smart ring maker Oura prepares for US IPO at up to $3b raise appeared first on Longevity.Technology.

Retro Biosciences is expanding its phase 1 safety trial of RTR 242 by adding two higher-dose cohorts and increasing enrollment from 76 to 108 participants, a more than 42% rise. The trial is being conducted in Australia in healthy volunteers aged 18 to 65. The company claims RTR 242 is designed to restore lysosomal acidity The post Retro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’s appeared first on Longevity.Technology.

Insilico Medicine released interim results for the first half of 2026, reporting total revenue of US$106.3 million, a year-over-year increase of 287.2%, and a gross profit margin of 90.3%. The company recorded a net profit of US$35.54 million, an adjusted net profit of US$51.23 million, positive operating cash flow, and held US$584.8 million in cash The post Insilico revenue surges 287% in H1 2026 driven by major pharma deals appeared first on Longevity.Technology.

A new study compared high-intensity sprint-interval exercise with moderate-intensity exercise. The former produced larger changes in circulating protein and metabolite levels than the latter and stimulated

HEALTH survey suggests the longevity conversation is shifting from living longer toward living better and the industry may need to catch up. HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, raises some uncomfortable questions for an industry racing toward the future: are biohackers building for an audience that doesn’t exist? While tech The post New survey reveals what Americans really want from longevity appeared first on Longevity.Technology.

Anavex reported a business update and financial results for the third fiscal quarter ended 30 June. The company has submitted all data from its Alzheimer’s disease clinical trials to a newly opened Alzheimer’s IND and intends to use EMA feedback and prior FDA interactions to inform a planned Phase 3 design. Anavex also reported that The post Anavex outlines progress in Alzheimer’s, rare disease studies with cash runway into 2028 appeared first on Longevity.Technology.

Alnylam will present new clinical and real-world data across its transthyretin-mediated amyloidosis and hypertension programs at ESC Congress 2026 in Munich on 28-31 August 2026. Presentations include late-breaking pre-specified analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) assessing outcomes in patients on background stabilizer therapy, additional HELIOS-B analyses of healthy aging, functional capacity, The post Alnylam showcases late-breaking heart treatment, hypertension findings at ESC 2026 appeared first on Longevity.Technology.

Eisai and Biogen announced that LEQEMBI IQLIK (lecanemab-irmb) autoinjector is now available in the U.S. for initiation of therapy in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, collectively referred to as early AD. For initiation, the approved regimen is 500 mg once weekly delivered as two consecutive 250 mg subcutaneous The post Eisai, Biogen launch at-home Leqembi autoinjector in the US for early Alzheimer’s appeared first on Longevity.Technology.

What if your healthcare could connect the dots between your bloodwork, sleep, genetics and everyday life – before something goes wrong? What if healthcare did not begin when you got sick? That question is the center of this week’s episode of Longevity.Technology UNLOCKED, in which ahead of this year’s Longevity Investors Conference, host Phil Newman The post Building a health system that puts prevention first appeared first on Longevity.Technology.

Self-contracting myografts improved muscle, bone and metabolic measures in aging mice – without requiring the animals to exercise. Researchers have engineered living muscle grafts that spontaneously contract beneath the skin and appear to reproduce some of exercise’s systemic effects, improving measures of muscle function, bone health and metabolism in aging mice [1]. The work, published The post Scientists create muscle that exercises itself appeared first on Longevity.Technology.

Blade Runner Lost Script Reveals Tyrell Froze Himself: Real Cryonics Has Same Fatal Flaw  Tech Times

These lab-grown balls of brain tissue could help researchers study a host of disorders that emerge as the brain ages. The post Mini Brains Grown for Five Years Matured Like Human Brains appeared first on SingularityHub.

Icahn School of Medicine wins $1m award as its NYC-Vita trial pushes toward the finals of the world’s biggest healthy aging competition. Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it The post Mount Sinai’s $1m XPRIZE bet: reset immune system, slow aging appeared first on Longevity.Technology.

Growth financing will help expand the Syn-One Test as investors place bigger bets on precision neurology and the future of earlier diagnosis. One of the biggest frustrations in neurology is that by the time diseases such as Parkinson’s become obvious, they have often been quietly progressing for years. The tremors, stiffness and movement problems people The post CND Life Sciences funding backs earlier Parkinson’s detection appeared first on Longevity.Technology.

AVLAYAH brought in $3.6 million in its first quarter, as Denali advanced its Alzheimer’s pipeline and banked $195m from a voucher sale. California-based Denali Therapeutics has posted its first quarterly revenue as a commercial-stage company, reporting $3.6 million in net product revenue from AVLAYAH (tividenofusp alfa-eknm) in the second quarter of 2026, its first full The post Denali Therapeutics’ brain-crossing drug hits market appeared first on Longevity.Technology.